002932，重大资产重组

Group 1 - The core point of the article is that Mingde Biological has signed a framework agreement with Bluefan Medical to acquire 100% equity of Wuhan Bikaier Rescue Supplies Co., Ltd. in a cash transaction, which will make the target company a wholly-owned subsidiary after completion [1][3]. - The transaction is expected to constitute a major asset restructuring as defined by the regulations, and it will not involve a restructuring listing or the issuance of shares [3]. - The target company specializes in emergency rescue products and has a strong foundation in both industrial emergency protection and consumer markets, which complements Mingde Biological's existing business in critical care diagnostics [4]. Group 2 - Mingde Biological aims to enhance its strategic focus on critical care business through this acquisition, which will help extend its integrated diagnostic and rescue services from medical institutions to industrial and household scenarios [4]. - The company has a comprehensive product matrix supported by ten technology platforms, covering various diagnostic product lines and providing services to over 7,500 medical institutions across China and more than 50 countries [3]. - The current stock price of Mingde Biological is reported at 17.82 yuan per share, with a total market capitalization of 4.144 billion yuan [6].